Avery C Lee
Overview
Explore the profile of Avery C Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee A, Pingali S, Pinilla-Ibarz J, Atchison M, Koumenis C, Argon Y, et al.
Leukemia
. 2022 Aug;
36(10):2430-2442.
PMID: 36042317
Activation-induced cytidine deaminase (AID) has been implicated as both a positive and a negative factor in the progression of B cell chronic lymphocytic leukemia (CLL), but the role that it...
2.
Shao A, Xu Q, Kang C, Cain C, Lee A, Tang C, et al.
Mol Pharm
. 2022 Mar;
19(4):1059-1067.
PMID: 35253431
Activation of the IRE-1/XBP-1s pathway supports tumor progression. Here, we report a novel prodrug, TC-D-F07, in which a thiol-reactive dinitrobenzenesulfonyl (Dns) cage was installed onto the C8 hydroxyl of the...
3.
Tang C, Lee A, Chang S, Xu Q, Shao A, Lo Y, et al.
Cell Mol Immunol
. 2020 Oct;
18(4):1016-1031.
PMID: 32999453
STING is an endoplasmic reticulum (ER)-resident protein critical for sensing cytoplasmic DNA and promoting the production of type I interferons; however, the role of STING in B cell receptor (BCR)...
4.
Goulart M, Hlavaty S, Chang Y, Polton G, Stell A, Perry J, et al.
Sci Rep
. 2019 Mar;
9(1):3574.
PMID: 30837603
Myeloid-derived suppressor cells (MDSCs) are key players in immune evasion, tumor progression and metastasis. MDSCs accumulate under various pathological states and fall into two functionally and phenotypically distinct subsets that...
5.
Ye S, Lawlor M, Rivera-Reyes A, Egolf S, Chor S, Pak K, et al.
Cancer Res
. 2018 Mar;
78(10):2705-2720.
PMID: 29490948
To date, no consistent oncogenic driver mutations have been identified in most adult soft tissue sarcomas; these tumors are thus generally insensitive to existing targeted therapies. Here we investigated alternate...